AJU S56
Alternative Names: AJU-S56Latest Information Update: 04 Apr 2024
At a glance
- Originator AJU Pharm
- Developer AJU Pharm; GL PharmTech
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 10 Nov 2023 Phase-III clinical trials in Dry eyes in South Korea (Intraocular) (NCT06291194)